Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders.[1] In 2018, the company was acquired by Mallinckrodt.

Sucampo Pharmaceuticals, Inc.
IndustryPharmaceutical industry
Founded1996 (1996)
DefunctFebruary 12, 2018 (2018-02-12)
FateAcquired by Mallinckrodt
HeadquartersRockville, Maryland
Key people
Peter Greenleaf (CEO and (Chairman)
Andrew P. Smith (CFO)
ProductsAmitiza
RevenueIncrease $230 million (2016)
Decrease $18 million (2016)
Total assetsIncrease $520 million (2016)
Total equityIncrease $167 million (2016)
Number of employees
139 (2017)
Websitewww.sucampo.com Edit this on Wikidata
Footnotes / references
[1]

Sucampo had two marketed products, Amitiza, which treats constipation issues and Rescula, which helps treat ocular hypertension and open-angle glaucoma. Takeda Pharmaceutical Company had a license to distribute Rescula globally except for in Japan and China. The company had two Phase III drugs in development for rare diseases — one for Niemann-Pick Type C and the other for familial adenomatous polyposis, which can cause colon cancer if untreated.[1]

History

The company was founded by Ryuji Ueno and Sachiko Kuno in 1996.[1]

In January 2006, the company received approval from the Food and Drug Administration for Amitiza.[2]

In 2010, the company entered into arbitration with its partner, Takeda Pharmaceutical Company, claiming that sales of Amitiza floundered because of a half-hearted marketing effort by Takeda. Sucampo lost the arbitration.[3]

In late 2015, the company moved its headquarters from Bethesda, Maryland to Rockville, Maryland.[4]

In January 2016, the company acquired an option for an exclusive license to a drug to treat familial adenomatous polyposis.[5]

In April 2017, the company acquired Vtesse.[6]

In February 2018, the company was acquired by Mallinckrodt. At that time, the founders owned a combined 30% of the company.[7]

References
  1. "Sucampo Pharmaceuticals, Inc. 2016 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
  2. "FDA Approves New Type of Drug To Treat Constipation in Adults". The Wall Street Journal. February 1, 2006.
  3. Flook, Bill (July 6, 2012). "Sucampo loses arbitration with pharma partner". American City Business Journals.
  4. Proctor, Carolyn M. (May 13, 2016). "3 things you should know about Greater Washington's bioscience companies". American City Business Journals.
  5. Reed, Tina (January 11, 2016). "Sucampo acquires exclusive option for cancer drug in deal worth up to $190 million". American City Business Journals.
  6. "Sucampo Acquires Vtesse Inc" (Press release). Globe Newswire. April 3, 2017.
  7. Reed, Tina (February 13, 2018). "Sucampo Pharmaceuticals closes on its $1.2B sale to a U.K. company". American City Business Journals.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.